Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
Centogene N.V. (symbol: CNTG) is a leading global company in the field of genetic diagnostic testing for rare hereditary diseases. With an expansive test portfolio covering over 2,800 genes, as well as biochemical and biomarker tests, the company offers unparalleled expertise in whole exome sequencing and whole genome sequencing. Centogene's mission is to provide data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by diagnosing the root causes of symptoms early on.
Centogene leverages its unique CentoMD® mutation database, integrating genetic and clinical information to deliver the highest quality genetic testing and biomarker development. This extensive database allows the company to maintain the largest systematic documentation of genetic results worldwide.
Beyond individual diagnostic services, Centogene is a pivotal partner for pharmaceutical companies, offering essential services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. The company operates in two main segments: pharmaceutical and diagnostics, serving regions including Europe, the Middle East, North America, and Latin America.
Recent achievements include the launch of innovative genomic and multiomic products, a significant joint venture in Saudi Arabia, and expanded collaborations with long-standing and new pharma partners. Despite the challenges posed by current financial markets, Centogene remains committed to growth and profitability, exploring strategic alternatives to unlock value for its stakeholders.
With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, Centogene's research and development efforts have led to over 285 peer-reviewed publications. The company's pioneering work in rare and neurodegenerative diseases has fostered collaborations with over 50 pharmaceutical partners, accelerating drug discovery and development.
To discover more about Centogene's products, pipeline, and patient-driven purpose, visit their website and follow them on LinkedIn.
Centogene N.V. (Nasdaq: CNTG) has announced the pricing of a public offering of 3,500,000 common shares at $14.00 each, aiming to raise $28 million for the company and $21 million for selling shareholders. The offering includes 2,000,000 shares from the company and 1,500,000 shares from shareholders. The underwriters have a 30-day option to purchase an additional 525,000 shares. Proceeds will support research and development for orphan drug initiatives, working capital, and potential acquisitions. The offering is set to close around July 14, 2020.
Centogene N.V. (Nasdaq: CNTG) announced the publication of its paper titled ‘Rapid Large-Scale COVID-19 Testing During Shortages’ in Diagnostics. The study highlights innovative testing solutions amidst the COVID-19 pandemic, contributing valuable insights to the medical community. CEO Prof. Arndt Rolfs emphasized their commitment to high-quality molecular diagnostics, particularly in supporting widespread SARS-CoV-2 testing. The company aims to enhance patient care through reliable testing and has established a testing service at Frankfurt airport, reinforcing its role in addressing public health challenges.
Centogene N.V. (Nasdaq: CNTG) has initiated an underwritten public offering of 3.5 million common shares, consisting of 2 million shares from the company and 1.5 million from selling shareholders, with an additional 525,000 shares available for underwriters. Proceeds from the offering will fund research and development for orphan drug initiatives, working capital, and potential investments in complementary businesses. The offering is dependent on market conditions and a registration statement is pending effectiveness.
Centogene N.V. (Nasdaq: CNTG) has partnered with OESIS Network to provide COVID-19 screening for schools across the U.S. The partnership will utilize RT-PCR testing at affordable prices, aimed at facilitating the safe return of students and staff to campus. Up to 50,000 tests per week will be available, with potential for increased capacity. The initiative emphasizes privacy, utilizing anonymized sample collection. With a focus on quality and logistics, Centogene's services will support both public and independent schools, potentially funded through the Cares Act.
Centogene N.V. (Nasdaq: CNTG) announced that the FDA has granted Emergency Use Authorization for its SARS-CoV-2 RT-PCR test. This test is designed for qualitative detection of the virus using upper respiratory samples. CEO Prof. Arndt Rolfs emphasized the company's commitment to high-quality diagnostics to combat COVID-19. The test, intended for use in CENTOGENE's certified laboratories in Germany, aims to facilitate early diagnosis and support public health initiatives. The company collaborates with pharmaceutical partners to enhance testing efficacy.
CENTOGENE (NASDAQ: CNTG) has partnered exclusively with Lufthansa and Fraport to offer COVID-19 testing for passengers at Frankfurt Airport. This initiative aims to facilitate safe international travel as restrictions ease. The testing service is now available and will continue until July 31, 2021. Passengers can access a convenient walk-in testing center, obtaining results via a secure digital platform, essential for travels to countries requiring testing. This collaboration represents a significant step towards normalizing air travel amid the pandemic.
Centogene N.V. (Nasdaq: CNTG) announced the resignation of Supervisory Board member Christoph Ehlers, effective June 15, 2020, due to personal circumstances. Ehlers served over six years and contributed significantly to the company's growth. CEO Prof. Arndt Rolfs expressed gratitude for Ehlers' role and noted his ongoing involvement. Centogene specializes in rare diseases, leveraging real-world clinical and genetic data to aid patients and pharmaceutical companies, boasting a repository of 3.0 billion weighted data points from over 530,000 patients across 120 countries as of March 31, 2020.
Centogene N.V. (Nasdaq: CNTG) reported €12.1 million in revenues for Q1 2020, marking a 13% increase year-over-year. The company continues expanding its rare disease platform, with approximately 3 billion data points from over 530,000 patients. Despite the challenges posed by COVID-19, Centogene launched its CentoSwab™ testing kit and expanded testing capabilities. However, the company reported a comprehensive loss of €8.6 million, or €0.43 per share, compared to €5.2 million, or €0.33 per share, in Q1 2019. R&D and G&A expenses also increased significantly.
Centogene N.V. (Nasdaq: CNTG) announced it will report its financial results for Q1 2020 on June 15, 2020. The earnings call will take place at 8 a.m. EST, where the company will discuss its financial performance and outlook. Centogene focuses on rare diseases, utilizing a platform that integrates clinical and genetic data from approximately 500,000 patients across 120 countries. The company collaborates with over 39 pharmaceutical partners to enhance orphan drug development. Interested participants can access the call by dialing provided numbers or via the company's Investor Relations webpage.
Centogene N.V (Nasdaq: CNTG) announced on May 15, 2020, that Chief Business Officer Oved Amitay will resign effective May 31, 2020. He will be succeeded by Sun Kim, currently the Chief Strategy and IR Officer. Prof. Arndt Rolfs, CEO, expressed gratitude for Amitay's contributions to the growth of the Pharma business, emphasizing Kim’s extensive experience in strategy and commercial operations as beneficial for future collaborations. Centogene focuses on rare diseases, utilizing a platform with approximately 2.5 billion data points from around 500,000 patients worldwide as of December 31, 2019.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
What does Centogene N.V. specialize in?
What is CentoMD®?
Which segments does Centogene operate in?
What regions does Centogene serve?
Who are Centogene’s main partners?
What are some recent achievements of Centogene?
How does Centogene contribute to drug discovery?
What research certifications does Centogene hold?
How extensive is Centogene's physician network?
Where can I learn more about Centogene?
